Skip to search formSkip to main content

naptumomab estafenatox

A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal… Expand
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

ABR-217620

Broader (3)

EnterotoxinsImmunoconjugatesMonoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 2712: Naptumomab Estafenatox induces T cell recognition, turning anti-PD-1 unresponsive "cold" tumors into "hot" responsive tumors
Tumor recognition is a key factor in checkpoint inhibitors (CPI) efficacy and acquired resistance. Lack or loss of tumor antigens… Expand
Is this relevant?
2017
2017
A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma.
3073 Background: Naptumomab estafenatox/ANYARA (Nap) is a fusion protein of an antibody (5T4) and a superantigen (SEA/E-120… Expand
Is this relevant?
2016
2016
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis.
PURPOSE To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α
Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies. RCC patients in the phase… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2014
Review
2014
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
Improvement of cancer therapy by introducing new concepts is still urgent even though there have been major advancements lately… Expand
  • figure 1
  • table 1
Is this relevant?
2013
2013
The Tumor Targeted Superantigen ABR-217620 Selectively Engages TRBV7-9 and Exploits TCR-pMHC Affinity Mimicry in Mediating T Cell Cytotoxicity
The T lymphocytes are the most important effector cells in immunotherapy of cancer. The conceptual objective for developing the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has… Expand
Is this relevant?
Review
2010
Review
2010
Naptumomab estafenatox: a new immunoconjugate.
IMPORTANCE OF THE FIELD New agents that specifically engage the immune system are being tested in a variety of malignancies. This… Expand
Is this relevant?
2009
2009
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung…
PURPOSE Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2006
2006
An open label phase I study of ABR-217620, a fusion protein of the 5T4 antibody moiety and an engineered superantigen, in patients with non-small cell lung, renal cell or pancreatic cancer.
3083 Background: ABR-217620 (naptumomab estafenatox) is a recombinant fusion protein that consists of the 5T4Fab moiety… Expand
Is this relevant?